Trials / Terminated
TerminatedNCT00086346
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 607 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus (Rapamune) | |
| DRUG | Cyclosporine or Tacrolimus |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2004-07-02
- Last updated
- 2010-04-28
- Results posted
- 2009-09-07
Locations
42 sites across 12 countries: United States, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00086346. Inclusion in this directory is not an endorsement.